63rd American Society of Hematology Annual Meeting and Exposition: Major Nurse Takeaways
February 12th 2022Oral Bruton tyrosine kinase inhibitors make notable strides in CLL treatment. Chimeric antigen receptor T-cell therapy continues to command attention by besting standard-of-care therapies.